Key Enzymes in Aromatic Amino Acid Metabolism: Mechanisms and Experimental Applications in Tryptophan, Tyrosine, and Phenylalanine Pathways

Aromatic amino acid metabolism mainly centers on tryptophan, tyrosine, and phenylalanine. Key enzymes determine how these amino acids are directed toward neurotransmitters, melanin, catecholamines, kynurenine, phenylpyruvate, and energy metabolism intermediates. This article focuses on the major metabolic pathways, key enzyme functions, disease mechanisms, experimental detection indicators, and result interpretation methods.

Keywords: aromatic amino acid metabolism; tryptophan metabolism; tyrosine metabolism; phenylalanine metabolism; IDO1; TDO2; PAH; TH; TPH; kynurenine pathway; catecholamines

1 Research Positioning of Aromatic Amino Acid Metabolism

1.1 Metabolic Substrates and Branching Directions

(1) Tryptophan

Tryptophan is an important precursor of serotonin, melatonin, kynurenine, and nicotinamide adenine dinucleotide-related metabolites. Most tryptophan does not enter the serotonin pathway, but is converted into the kynurenine pathway through IDO1, IDO2, or TDO2. This pathway is closely associated with immunosuppression, inflammatory responses, the tumor microenvironment, neurotoxicity, and energy metabolism.

(2) Tyrosine

Tyrosine can be obtained from dietary intake or generated from phenylalanine hydroxylation. Tyrosine further participates in catecholamine synthesis, thyroid hormone synthesis, melanin production, and degradation toward fumarate/acetoacetate-related metabolic routes. Tyrosine hydroxylase, tyrosinase, 4-hydroxyphenylpyruvate dioxygenase, and fumarylacetoacetate hydrolase are important control points in this pathway.

(3) Phenylalanine

Phenylalanine is mainly converted to tyrosine by phenylalanine hydroxylase. Reduced PAH activity leads to phenylalanine accumulation and formation of abnormal metabolites such as phenylpyruvate, phenyllactate, and phenylacetate. This is the core pathway in phenylketonuria mechanism research and newborn screening.

1.2 Research Value

(1) Inherited metabolic disease research

Phenylketonuria, tyrosinemia, and alkaptonuria are all associated with abnormalities in aromatic amino acid metabolic enzymes. These studies usually require combined detection of substrates, products, intermediate metabolites, enzyme activity, and genetic variants. Pathway status should not be judged by a single amino acid concentration alone.

(2) Neurological and endocrine research

Tryptophan and tyrosine participate in the production of serotonin, melatonin, dopamine, norepinephrine, and epinephrine. Enzymes such as TPH, AADC/DDC, TH, DBH, and PNMT control neurotransmitter synthesis efficiency and are suitable for research on neuropsychiatric disorders, stress responses, sleep rhythms, and neuroendocrine regulation.

(3) Immunology and tumor research

IDO1 and TDO2 can reduce local tryptophan levels and increase kynurenine production, affecting T-cell function, regulatory T-cell differentiation, and tumor immune escape. In tumor, chronic inflammation, and infection models, the tryptophan/kynurenine ratio is commonly used to reflect pathway activation.

Table 1 Aromatic Amino Acid Metabolic Directions and Representative Key Enzymes

Metabolic Substrate	Main Pathway	Key Enzymes	Representative Detection Indicators
Tryptophan	Kynurenine pathway	IDO1, IDO2, TDO2	Tryptophan, kynurenine, Kyn/Trp ratio
Tryptophan	Serotonin/melatonin pathway	TPH1, TPH2, AADC/DDC, AANAT, ASMT	5-HT, 5-HIAA, melatonin
Phenylalanine	Phenylalanine hydroxylation pathway	PAH	Phenylalanine, tyrosine, Phe/Tyr ratio
Tyrosine	Catecholamine synthesis	TH, AADC/DDC, DBH, PNMT	L-DOPA, dopamine, norepinephrine, epinephrine
Tyrosine	Melanin synthesis	TYR, TYRP1, DCT/TYRP2	Tyrosinase activity, melanin, TRP1/TRP2
Tyrosine	Degradation metabolism	TAT, HPD, HGD, FAH	4-HPP, homogentisic acid, succinylacetone

2 Key Enzymes in Tryptophan Metabolism

2.1 Kynurenine Pathway

(1) IDO1

IDO1 catalyzes the conversion of tryptophan to N-formylkynurenine and is an important rate-limiting enzyme in immune-related tryptophan catabolism. IFN-γ, TNF-α, LPS, and the tumor microenvironment can all induce IDO1 expression. Upregulation of IDO1 usually indicates enhanced tryptophan consumption and increased kynurenine production. However, whether an immunosuppressive state is formed still requires combined analysis of T-cell proliferation, Treg proportion, inflammatory cytokines, and downstream kynurenine metabolites.

(2) IDO2

IDO2 belongs to the indoleamine 2,3-dioxygenase family together with IDO1, but differs in tissue distribution, catalytic efficiency, and immunoregulatory characteristics. IDO2 is often used to explain residual tryptophan catabolic activity after IDO1 inhibition, or to stratify pathways in autoimmune disease, chronic inflammation, and tumor models.

(3) TDO2

TDO2 is mainly expressed in the liver, but may also be abnormally upregulated in some tumor tissues. It plays an important role in systemic tryptophan homeostasis and is highly valuable in studies of hepatic metabolism, stress hormone responses, tumor immune escape, and kynurenine generation. Compared with IDO1, TDO2 is more closely associated with basal metabolism and liver-derived tryptophan clearance.

2.2 Downstream Enzymes in the Kynurenine Pathway

(1) KMO

Kynurenine 3-monooxygenase converts kynurenine to 3-hydroxykynurenine and is an important node directing the kynurenine pathway toward neuroactive metabolites. Increased KMO activity may increase 3-hydroxykynurenine and quinolinic acid production, participating in research on oxidative stress, neuroinflammation, and excitotoxicity.

(2) KYNU

Kynureninase participates in further cleavage of kynurenine and 3-hydroxykynurenine, affecting the formation of anthranilic acid, 3-hydroxyanthranilic acid, and downstream quinolinic acid. If only kynurenine is measured experimentally, it is difficult to determine whether the pathway is diverted toward neuroprotective or neurotoxic branches.

(3) KAT

Kynurenine aminotransferase converts kynurenine to kynurenic acid. Kynurenic acid is usually regarded as a metabolite with NMDA receptor antagonist activity and neuromodulatory effects. The relative activities of KAT and KMO are commonly used to evaluate the branching balance of the kynurenine pathway.

2.3 Serotonin and Melatonin Pathways

(1) TPH1 and TPH2

Tryptophan hydroxylase catalyzes the formation of 5-hydroxytryptophan from tryptophan and is the rate-limiting step in serotonin synthesis. TPH1 is mainly associated with peripheral tissues and enterochromaffin cells, whereas TPH2 is mainly associated with the central nervous system. Studies should distinguish peripheral 5-HT metabolism from central 5-HT synthesis. Serum 5-HT alone should not be used to infer brain serotonin status.

(2) AADC/DDC

Aromatic L-amino acid decarboxylase converts 5-hydroxytryptophan to serotonin and also participates in the conversion of L-DOPA to dopamine. Therefore, AADC/DDC is not specific to the tryptophan pathway; it is an important shared node linking 5-HT and catecholamine synthesis.

(3) AANAT and ASMT

AANAT catalyzes the conversion of 5-HT to N-acetyl-5-hydroxytryptamine, while ASMT participates in the terminal methylation step of melatonin synthesis. If the study focuses on tryptophan diversion toward melatonin, 5-HT, N-acetyl-5-hydroxytryptamine, melatonin, and circadian sampling time should all be considered.

Table 2 Key Enzymes in Tryptophan Metabolism and Experimental Interpretation

Key Enzyme	Pathway	Main Function	Interpretation Point
IDO1	Kynurenine pathway	Inducible tryptophan catabolism	Should be analyzed with Kyn/Trp ratio and immune indicators
IDO2	Kynurenine pathway	Supplementary or tissue-specific catabolism	Often analyzed together with IDO1
TDO2	Kynurenine pathway	Hepatic and tumor-related tryptophan clearance	Distinguish hepatic metabolism from local immune effects
KMO	Downstream kynurenine pathway	Promotes 3-hydroxykynurenine formation	Related to neuroinflammation and oxidative stress
KYNU	Downstream kynurenine pathway	Promotes downstream quinolinic acid-related metabolism	Requires downstream metabolite analysis
TPH1/TPH2	5-HT synthesis	Catalyzes 5-hydroxytryptophan formation	Distinguish peripheral and central sources
AADC/DDC	Monoamine synthesis	Generates 5-HT or dopamine	Not specific to a single pathway
AANAT/ASMT	Melatonin synthesis	Participates in melatonin production	Strongly affected by sampling time

3 Key Enzymes in Phenylalanine and Tyrosine Metabolism

3.1 Phenylalanine Hydroxylation Pathway

(1) PAH

Phenylalanine hydroxylase catalyzes the conversion of phenylalanine to tyrosine and is the core rate-limiting enzyme in phenylalanine metabolism. When PAH function decreases, phenylalanine increases, tyrosine becomes relatively insufficient, and bypass metabolites such as phenylpyruvate appear. In phenylketonuria research, the Phe/Tyr ratio usually better reflects the degree of pathway blockage than phenylalanine concentration alone.

(2) BH4-related enzymes

The PAH reaction requires tetrahydrobiopterin as a cofactor. Abnormalities in BH4 synthesis and regeneration enzymes such as GCH1, PTS, and QDPR can also cause hyperphenylalaninemia. If phenylalanine is elevated but PAH gene or protein abnormalities are not obvious, BH4 metabolism-related indicators should be further analyzed.

(3) Phenylalanine bypass metabolism

When the PAH pathway is blocked, phenylalanine can form phenylpyruvate through transamination and further generate phenyllactate and phenylacetate. Increased levels of these bypass metabolites in urine or blood can help determine the metabolic consequences of phenylalanine accumulation.

3.2 Tyrosine Degradation Pathway

(1) TAT

Tyrosine aminotransferase converts tyrosine to 4-hydroxyphenylpyruvate and is one of the initiating steps in tyrosine degradation. TAT abnormalities can lead to tyrosinemia type II, often associated with elevated blood tyrosine and corneal and skin symptoms. Experimental analysis can combine tyrosine, 4-hydroxyphenylpyruvate, and TAT expression.

(2) HPD

4-Hydroxyphenylpyruvate dioxygenase catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisic acid. HPD participates in the middle stage of tyrosine degradation and is also commonly used as a drug intervention target to regulate production of downstream toxic metabolites.

(3) HGD

Homogentisate 1,2-dioxygenase is responsible for further degradation of homogentisic acid. HGD deficiency leads to homogentisic acid accumulation and is the key mechanism of alkaptonuria. Homogentisic acid can undergo oxidative polymerization and deposit in connective tissues. Related studies should focus on homogentisic acid levels, tissue pigment deposition, and oxidative stress.

(4) FAH

Fumarylacetoacetate hydrolase is the terminal key enzyme in tyrosine degradation. FAH deficiency causes tyrosinemia type I and is associated with accumulation of fumarylacetoacetate, succinylacetoacetate, and succinylacetone. Succinylacetone is an important detection indicator of this pathway abnormality.

3.3 Catecholamine Synthesis Pathway

(1) TH

Tyrosine hydroxylase catalyzes the conversion of tyrosine to L-DOPA and is the rate-limiting enzyme in catecholamine synthesis. TH expression and phosphorylation status are commonly used to evaluate dopaminergic neuron function, sympathetic activity, and stress response. Detecting increased TH protein alone does not necessarily indicate increased dopamine production; L-DOPA, dopamine, and metabolites should also be measured.

(2) AADC/DDC

AADC/DDC converts L-DOPA to dopamine and also participates in 5-HT synthesis. AADC/DDC activity is affected by tissue type, cofactor status, and substrate availability. If dopamine synthesis is being studied, TH, AADC/DDC, dopamine, DOPAC, and HVA should be detected together.

(3) DBH and PNMT

DBH catalyzes the conversion of dopamine to norepinephrine, and PNMT catalyzes the conversion of norepinephrine to epinephrine. Both are important in studies of sympathetic nerves and adrenal medulla function. Changes in DBH and PNMT expression should be interpreted in combination with tissue source, stress status, and plasma or tissue catecholamine levels.

3.4 Melanin Synthesis Pathway

(1) TYR

Tyrosinase catalyzes the conversion of tyrosine to L-DOPA and dopaquinone and is the key rate-limiting enzyme in melanin synthesis. TYR activity affects melanin production, pigmentation, albinism mechanisms, and melanoma cell phenotype. Tyrosinase activity detection is usually closer to functional status than mRNA levels alone.

(2) TYRP1 and DCT/TYRP2

TYRP1 and DCT/TYRP2 participate in subsequent reactions in melanin synthesis and affect eumelanin production, pigment stability, and melanosome maturation. When studying the melanin pathway, tyrosine uptake, TYR activity, total melanin content, and cell proliferation status should be distinguished.

Table 3 Key Enzymes in Phenylalanine and Tyrosine Metabolism and Disease Associations

Key Enzyme	Metabolic Node	Related Disease or Research Direction	Recommended Detection Combination
PAH	Phenylalanine → tyrosine	Phenylketonuria	Phe, Tyr, Phe/Tyr, phenylpyruvate
GCH1/PTS/QDPR	BH4 synthesis and regeneration	BH4 deficiency-related hyperphenylalaninemia	BH4, pterin profile, Phe
TAT	Tyrosine → 4-HPP	Tyrosinemia type II	Tyr, 4-HPP, TAT expression
HPD	4-HPP → homogentisic acid	Regulation of tyrosine degradation	4-HPP, homogentisic acid
HGD	Homogentisic acid degradation	Alkaptonuria	Homogentisic acid, oxidative deposition indicators
FAH	Terminal tyrosine degradation	Tyrosinemia type I	Succinylacetone, Tyr, liver injury indicators
TH	Tyrosine → L-DOPA	Dopamine synthesis, neurodegenerative diseases	TH, L-DOPA, dopamine
TYR	Melanin synthesis	Pigmentation, albinism, melanoma	TYR activity, melanin content

4 Experimental Detection Methods and Result Interpretation

4.1 Metabolite Detection

(1) LC-MS/MS

LC-MS/MS is suitable for simultaneous detection of tryptophan, kynurenine, tyrosine, phenylalanine, L-DOPA, dopamine, and organic acid metabolites. This method has strong specificity and is suitable for plasma, urine, brain tissue, cell culture supernatants, and tissue extracts. The stability of aromatic amino acids and their metabolites varies considerably, and sample collection, antioxidant protection, and low-temperature storage can affect results.

(2) HPLC

HPLC can be used to detect amino acids, catecholamines, 5-HT, and melanin-related precursors. Electrochemical detection is suitable for catecholamines, while fluorescence or UV detection can be used for some indole and aromatic metabolites. Method selection should be based on target concentration, matrix complexity, and required detection sensitivity.

(3) Ratio indicators

The Kyn/Trp ratio is commonly used to evaluate tryptophan diversion into the kynurenine pathway. The Phe/Tyr ratio is commonly used to assess PAH pathway efficiency. DOPAC/DA or HVA/DA can be used to analyze dopamine turnover. Ratio indicators help reflect pathway direction, but cannot replace absolute concentration and enzyme activity validation.

4.2 Enzyme Expression and Enzyme Activity Detection

(1) mRNA and protein expression

qPCR, Western blot, immunohistochemistry, immunofluorescence, and ELISA can be used to detect expression of key enzymes such as IDO1, TDO2, PAH, TH, and TYR. Increased expression suggests that the pathway may be activated, but it does not equal increased enzyme activity. Cofactor deficiency, substrate limitation, inhibitor presence, or abnormal post-translational modification can all cause inconsistencies between expression and function.

(2) Enzyme activity detection

Enzyme activity detection is closer to functional status. TH activity can be analyzed by L-DOPA production, TYR activity by L-DOPA oxidation or dopaquinone formation, and IDO1/TDO2 activity by kynurenine generation. Enzyme activity experiments should include substrate blanks, heat-inactivated enzyme controls, positive inhibitors, and a linear time range.

(3) Gene function validation

siRNA, gene knockout lysates, recombinant proteins, and specific inhibitors can be used for key enzyme function validation. After pathway intervention, substrate reduction, product increase, or bypass metabolic changes should be detected to avoid inferring enzyme function only from endpoint phenotypes.

4.3 Cell and Animal Model Design

(1) Cell models

Tumor cells, immune cells, hepatocytes, neurons, and melanocytes are suitable for studying different aromatic amino acid pathways. IDO1 studies commonly use inflammatory factor induction or tumor-immune co-culture systems. TH studies are common in dopaminergic neuron models. TYR studies are commonly performed in melanocytes or melanoma cells.

(2) Animal models

Hyperphenylalaninemia, tyrosinemia, tumor immunity, neurodegenerative disease, and depression-like behavior models may all involve aromatic amino acid metabolism. Animal experiments should consider tissue specificity. Changes in blood metabolites do not necessarily reflect metabolic status in the brain, liver, or local tumor environment.

(3) Intervention validation

Inhibitors, siRNA, CRISPR knockout, overexpression, and substrate/cofactor supplementation can be used to validate key enzyme functions. After pathway intervention, substrate reduction, product increase, or bypass metabolic changes should be detected to avoid inferring enzyme function only from endpoint phenotypes.

Table 4 Common Detection Strategies in Aromatic Amino Acid Metabolism Research

Research Objective	Recommended Samples	Core Detection Indicators	Interpretation Focus
IDO1/TDO2 activation	Plasma, tumor tissue, cell supernatant	Trp, Kyn, Kyn/Trp	Analyze together with immune cell function
PAH pathway abnormality	Blood, urine, liver tissue	Phe, Tyr, Phe/Tyr, phenylpyruvate	Distinguish PAH deficiency from BH4 deficiency
Catecholamine synthesis	Brain tissue, neurons, plasma	TH, L-DOPA, DA, DOPAC, HVA	Expression, enzyme activity, and metabolites should be combined
Melanin production	Melanocytes, skin tissue	TYR activity, L-DOPA oxidation, melanin content	Correct for cell number and proliferation differences
Tyrosine degradation abnormality	Blood, urine, liver tissue	Tyr, homogentisic acid, succinylacetone	Identify the blocked position in the degradation pathway
Neuroinflammatory metabolism	Brain tissue, cerebrospinal fluid, plasma	Kyn, 3-HK, KYNA, QA	Determine the branching direction of kynurenine metabolism

5 Application Scenarios of Key Enzymes in Aromatic Amino Acid Metabolism

5.1 Diagnosis and Mechanism Research of Inherited Metabolic Diseases

(1) Phenylketonuria

PAH deficiency causes phenylalanine elevation and is the core mechanism of phenylketonuria. Experimental research should simultaneously focus on PAH gene variants, PAH protein expression, BH4 responsiveness, Phe/Tyr ratio, and bypass metabolites. For suspected BH4 deficiency cases, pterin profiles and neurotransmitter-related metabolites should also be measured.

(2) Tyrosinemia

Abnormalities in TAT, HPD, HGD, and FAH in the tyrosine degradation pathway can lead to different types of metabolic diseases. FAH deficiency-related tyrosinemia type I places greater emphasis on succinylacetone and liver injury indicators; HGD abnormality focuses more on homogentisic acid accumulation and tissue deposition.

5.2 Tumor Immunity and Inflammatory Microenvironment

(1) IDO1 pathway

IDO1 is upregulated in many tumors and inflammatory tissues and can regulate immune responses through tryptophan consumption and kynurenine production. Experiments should avoid using IDO1 expression alone to judge immunosuppression. Kynurenine, T-cell function, Treg proportion, and immune checkpoint molecules should be detected together.

(2) TDO2 pathway

TDO2 participates in kynurenine production in some tumors and may be associated with AHR signaling, immune escape, and tumor metabolic adaptation. If kynurenine levels remain high after IDO1 inhibition, the contribution of TDO2 or downstream metabolic enzymes should be considered.

5.3 Neurotransmitter and Neurometabolism Research

(1) Serotonin pathway

TPH, AADC/DDC, and MAO jointly influence 5-HT synthesis and degradation. In depression, sleep, gut-brain axis, and inflammation-related behavioral studies, tryptophan availability, kynurenine diversion, and 5-HT metabolites should be analyzed together.

(2) Catecholamine pathway

TH is the key rate-limiting enzyme in dopamine synthesis and is commonly used in studies of Parkinson’s disease, stress response, and sympathetic activity. Reduced TH expression, decreased L-DOPA, and altered dopamine metabolites together support impairment of the dopamine pathway. TH immunostaining alone is insufficient to fully explain catecholamine metabolic status.

5.4 Pigment Production and Melanocyte Research

(1) Tyrosinase activity

TYR activity directly affects the rate of melanin production. In whitening activity screening, albinism models, melanoma phenotype research, and pigmentation mechanism analysis, TYR activity, melanin content, and cell viability should be measured simultaneously.

(2) Melanin pathway stratification

TYRP1, DCT/TYRP2, and related transport proteins affect melanin maturation and melanosome function. If an intervention reduces melanin content, false reductions caused by cytotoxicity, proliferation inhibition, or reduced tyrosine uptake should be excluded.

6 Key Considerations in Experimental Design

6.1 Distinguishing Expression, Activity, and Metabolic Flux

(1) Expression does not equal flux

Increased expression of key enzymes suggests the possibility of pathway activation, but final metabolic flux depends on substrate availability, cofactors, enzyme activity, cellular compartmentalization, and product feedback. Enzymes such as IDO1, TH, and TYR may all show incomplete consistency between expression and metabolite changes.

(2) Flux requires metabolite support

When evaluating changes in aromatic amino acid pathways, both substrates and products should be measured at minimum. Measuring only tryptophan decrease, phenylalanine elevation, or tyrosine change cannot clearly identify the specific blockage or branching point.

6.2 Emphasizing Tissue Specificity

(1) Liver and periphery

TDO2 and PAH are more liver-oriented metabolic enzymes, while peripheral blood metabolites are often affected by liver function, diet, and systemic inflammation. Plasma data are suitable for reflecting systemic status, but cannot directly replace local tissue metabolism analysis.

(2) Central nervous system and periphery

TPH2, TH, and some kynurenine metabolites are closely related to the central nervous system. Changes in peripheral blood tryptophan or 5-HT cannot be simply equated with changes in brain neurotransmitters. Brain tissue, cerebrospinal fluid, or neuronal cell models are needed for validation.

6.3 Controlling Sample Pretreatment

(1) Oxidative stability

Catecholamines, L-DOPA, 5-HT, and some indole metabolites are sensitive to oxidation, light, and temperature. Samples should be rapidly processed at low temperature after collection, and suitable stabilizers or antioxidant conditions should be added according to the target analytes.

(2) Diet and circadian rhythm

Tryptophan, tyrosine, phenylalanine, and melatonin-related metabolites are affected by diet and circadian rhythm. Animal experiments and clinical sample studies should standardize sampling time, feeding status, and sample type.

(3) Cell number and tissue amount normalization

In cell models, metabolite concentrations should be normalized to cell number, protein content, or DNA content. For tissue samples, sampling site, sample weight, and extraction conditions should be standardized to avoid false pathway changes caused by sample amount differences.

7 Products Related to Key Enzymes in Aromatic Amino Acid Metabolism

Table 5 Products Related to Key Enzymes in Aromatic Amino Acid Metabolism

Cat. No.	Product Name	Grade/Specification	Related Enzyme/Pathway	Application Positioning
EJ1513984	Human Indoleamine 2,3-Dioxygenase 1(IDO1) ELISA Kit	BioReagent	IDO1; tryptophan-kynurenine pathway	Used to detect IDO1 protein levels in human samples and evaluate inflammation-induced tryptophan catabolism and tumor immunometabolic status
EJ1512023	Rat Indoleamine-2,3-Dioxygenase (IDO) ELISA Kit	BioReagent	IDO; tryptophan-kynurenine pathway	Used to detect IDO-related proteins in rat models, suitable for inflammation, tumor, and immunometabolism studies
EJ1512726	Mouse Indoleamine-2,3-Dioxygenase 1 (IDO1) ELISA Kit	BioReagent	IDO1; tryptophan-kynurenine pathway	Used for IDO1 detection in mouse tissue, serum, or cell samples and evaluation of Kyn/Trp pathway activation
EJ1514784	Human Tryptophan-2,3-dioxygenase (TDO) ELISA Kit	BioReagent	TDO/TDO2; tryptophan-kynurenine pathway	Used to detect TDO in human samples and evaluate hepatic or tumor-related tryptophan clearance
T1488296	TDO2 Human Pre-designed siRNA Set A		TDO2; gene function validation	Used for TDO2 knockdown to validate tryptophan diversion toward kynurenine in liver or tumor cells
H1442464	human TDO2-IN-1		TDO2 inhibitor	Used for TDO2 inhibition, tryptophan clearance blockade, and validation of TDO2-dependent kynurenine generation
K1483845	KMO Human Pre-designed siRNA Set A		KMO; downstream kynurenine pathway	Used for KMO knockdown to analyze kynurenine diversion toward 3-hydroxykynurenine
R168334	Ro 61-8048	≥98%(HPLC)	KMO inhibitor	Used for KMO inhibition, neuroinflammation, and downstream kynurenine pathway branching studies
U287879	UPF 648	≥98%(HPLC)	KMO inhibitor	Used for KMO pathway blockade and evaluation of 3-HK and KYNA branching changes
T171759	Telotristat	Moligand™, ≥97%	TPH inhibitor	Used to inhibit tryptophan diversion toward serotonin and evaluate regulation of 5-HT generation
EJ1514785	Human Tryptophan Hydroxylase 1 (TPH1) ELISA Kit	BioReagent	TPH1; peripheral 5-HT synthesis	Used to detect TPH1 in human samples and evaluate the peripheral tryptophan-5-HT pathway
EJ1514786	Human Tryptophan Hydroxylase 2 (TPH2) ELISA Kit	BioReagent	TPH2; central 5-HT synthesis	Used to detect TPH2 in human samples and support research on central 5-HT synthesis
EJ1513168	Mouse Tryptophan 5-hydroxylase 1 (TPH) ELISA Kit	BioReagent	TPH; 5-HT synthesis	Used to detect tryptophan hydroxylase in mouse models
EJ1513169	Mouse Tryptophan Hydroxylase 2 (TPH2) ELISA Kit	BioReagent	TPH2; central 5-HT synthesis	Used to detect TPH2 in mouse brain tissue or related models
EJ1514039	Human Dopa Decarboxylase (DDC) ELISA Kit	BioReagent	DDC/AADC; monoamine synthesis	Used to detect DDC in human samples and evaluate the shared node in 5-HT and dopamine synthesis
EJ1512288	Rat Arylalkylamine-N-Acetyltransferase (AANAT) ELISA Kit	BioReagent	AANAT; melatonin synthesis	Used to detect AANAT in rat samples and evaluate the melatonin synthesis pathway
EJ1514793	Human Phenylalanine Hydroxylase (PAH) ELISA Kit	BioReagent	PAH; phenylalanine hydroxylation pathway	Used to detect PAH in human samples and evaluate Phe→Tyr conversion capacity
EJ1513174	Mouse Phenylalanine Hydroxylase (PAH) ELISA Kit	BioReagent	PAH; phenylalanine hydroxylation pathway	Used to detect PAH in mouse models and support hyperphenylalaninemia and PKU research
P1520526	Phenylalanine hydroxylase (PAH)	Bioactive, Recombinant, ActiBioPure™, High Performance, EnzymoPure™, ≥90%(SDS-PAGE), ≥65 U/mg enzyme powder	Recombinant PAH enzyme	Used for PAH enzyme activity assays, substrate conversion, and establishment of phenylalanine hydroxylation reaction systems
Ab105011	GCH1 Mouse mAb	ExactAb™, Validated, See COA	GCH1 antibody	Used to detect GCH1 protein, a key enzyme in BH4 synthesis
rp188422	Recombinant Human QDPR/DHPR Protein	Carrier Free,His Tag,≥85%(SDS-PAGE),See COA	Recombinant QDPR protein	Used for BH4 regeneration-related reactions, enzymology studies, and protein function validation
Ab108629	HPD Mouse mAb	Carrier Free, ExactAb™, Azide Free, Validated, High Performance, See COA	HPD antibody	Used for HPD protein detection and tyrosine degradation pathway research
Ab107413	Recombinant HGD Antibody	Recombinant, ExactAb™, Validated, See COA	HGD antibody	Used for HGD protein detection and tyrosine degradation pathway validation
F1480750	FAH Human Pre-designed siRNA Set A		FAH; terminal tyrosine degradation	Used for FAH knockdown to analyze tyrosinemia type I-related metabolic blockage
T1441521	Tyrosine 3-monooxygenase		TH; catecholamine synthesis	Used for enzymology studies related to tyrosine conversion to L-DOPA
EJ1513313	Mouse Tyrosine Hydroxylase (TH) ELISA Kit	BioReagent	TH; catecholamine synthesis	Used to detect TH in mouse samples and evaluate the early step of dopamine synthesis
P1437365	Phenylethanolamine N-methyl transferase, bovine		PNMT; catecholamine synthesis	Used for enzymology studies related to conversion of norepinephrine to epinephrine
EJ1514794	Human Phenylethanolamine N-methyltransferase(PNMT) ELISA Kit	BioReagent	PNMT; catecholamine synthesis	Used to detect PNMT in human samples and evaluate epinephrine synthesis capacity
L287279	LY 78335	≥98%	PNMT inhibitor	Used for PNMT inhibition, epinephrine generation blockade, and stress pathway research
EJ1513903	Human Monoamine Oxidase B (MAO-B) ELISA Kit	BioReagent	MAOB; monoamine degradation	Used to detect MAO-B in human samples and evaluate degradation pathways of dopamine and other monoamines
EJ1512700	Mouse Monoamine Oxidase (MAO) ELISA Kit	BioReagent	MAO; monoamine degradation	Used for total MAO-related detection in mouse samples
EJ1512701	Mouse Monoamine Oxidase A (MAOA) ELISA Kit	BioReagent	MAOA; monoamine degradation	Used to detect MAOA in mouse samples and evaluate degradation of 5-HT and catecholamines
EJ1512011	Rat Monoamine Oxidase A (MAOA) ELISA Kit	BioReagent	MAOA; monoamine degradation	Used to detect MAOA in rat samples
M1515932	Monoamine Oxidase (MAO) Activity Assay Kit (UV Micro Method)	BioReagent	MAO activity detection	Used to detect monoamine oxidase activity in micro systems
M1515933	Monoamine Oxidase (MAO) Activity Assay Kit (UV Colorimetric Method)	BioReagent	MAO activity detection	Used to evaluate monoamine oxidase activity in colorimetric systems
M1515882	Monoamine Oxidase (MAO) Activity Assay Kit (Aldehyde Phenylhydrazone, Micro Method)	BioReagent	MAO activity detection	Used to detect monoamine degradation capacity and study neurotransmitter metabolism
M1515883	Monoamine Oxidase (MAO) Activity Assay Kit (Aldehyde Phenylhydrazone, Colorimetric Method)	BioReagent	MAO activity detection	Used for colorimetric detection of MAO activity
rp329356	Recombinant Human MAOA Protein	≥95%(SDS-PAGE)	Recombinant MAOA protein	Used for MAOA enzymology studies and establishment of activity systems
rp329526	Recombinant Human MAOB Protein	≥90%(SDS-PAGE)	Recombinant MAOB protein	Used for MAOB enzymology studies and inhibitor evaluation
rp330262	Recombinant Rat MAOB Protein	≥90%(SDS-PAGE)	Recombinant MAOB protein	Used for rat MAOB-related enzymology research
Ab115808	Recombinant Monoamine Oxidase B/MAOB Antibody	ExactAb™, Validated, Recombinant, 2.0 mg/mL	MAOB antibody	Used for MAOB protein detection and monoamine degradation pathway research
C1440858	Catechol O-methyltransferase, porcine liver		COMT; catecholamine degradation	Used for catecholamine methylation reactions and COMT enzymology studies
Ab097283	COMT Antibody	Carrier Free, ExactAb™, Azide Free, Validated, High Performance, See COA	COMT antibody	Used for COMT protein detection and catecholamine degradation pathway analysis
C1482117	COMT Human Pre-designed siRNA Set A		COMT; gene function validation	Used for COMT knockdown to analyze dopamine and catecholamine methylation metabolism
O287664	OR-486	≥98%	COMT inhibitor	Used for COMT inhibitor research and intervention in dopamine degradation pathways
rp184883	Recombinant Human COMT Protein	Carrier Free,Bioactive,ActiBioPure™,His Tag,≥95%(SDS-PAGE),See COA	Recombinant COMT protein	Used for COMT enzyme activity, inhibitor screening, and methylation metabolism experiments
T1508158	Tyrosinase (TYR)	Bioactive,Recombinant,ActiBioPure™,High Performance,Suitable for molecular biology,EnzymoPure™,≥500U/mg enzyme powder；Protein Content ≥90% ; expressed in Yeast	Recombinant TYR enzyme	Used for tyrosinase activity, L-DOPA oxidation, and melanin synthesis research
T128536	Tyrosinase from mushroom	EnzymoPure™, ≥500 units/mg dry weight	Natural TYR enzyme	Used for tyrosinase substrate reactions, inhibitor screening, and melanin production experiments
rp221965	Recombinant Tyrosinase (TYR)	Bioactive,Recombinant,ActiBioPure™,High Performance,EnzymoPure™,≥90%(SDS-PAGE),≥25 U/μL	Recombinant TYR enzyme	Used for high-activity tyrosinase reaction systems and inhibitor evaluation
EJ1513314	Mouse Tyrosinase (TyR) ELISA Kit	BioReagent	TYR; melanin synthesis	Used to detect tyrosinase in mouse samples and evaluate the melanin synthesis pathway
P275741	PAP-AMC	≥97%	TYR fluorescent substrate	Used for tyrosinase activity detection and inhibitor screening
W287593	WIKI4	≥98%(HPLC)	TYR inhibitor	Used for tyrosinase inhibition, melanin reduction, and pigment pathway validation
EJ1513315	Mouse Tyrosinase-related Protein 1 (TRP1) ELISA Kit	BioReagent	TYRP1/TRP1; melanin synthesis	Used to detect TYRP1 in mouse samples and evaluate eumelanin production and melanosome maturation
EJ1513316	Mouse Tyrosine-related Protein 2 (TRP2) ELISA Kit	BioReagent	DCT/TYRP2; melanin synthesis	Used to detect TRP2 in mouse samples and analyze dopachrome conversion and melanin branch pathways
Ab176073	Flanvotumab (anti-TYRP1)	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	TYRP1-targeting antibody	Used for TYRP1-related melanoma, melanin pathway, and targeting research

8 Common Questions

8.1 What indicators are most commonly detected in aromatic amino acid metabolism research?

Common indicators include tryptophan, kynurenine, phenylalanine, tyrosine, Phe/Tyr ratio, Kyn/Trp ratio, L-DOPA, dopamine, 5-HT, homogentisic acid, and succinylacetone. The specific choice depends on the research direction. Immunometabolism focuses more on IDO1/TDO2 and the kynurenine pathway; inherited metabolic disease research focuses more on PAH and tyrosine degradation enzymes; neurological research focuses more on TPH, TH, and monoamine metabolites.

8.2 Does increased IDO1 expression necessarily mean enhanced immunosuppression?

Not necessarily. Increased IDO1 expression indicates that the tryptophan degradation pathway may be induced, but whether immunosuppression is enhanced also depends on kynurenine production, AHR signaling, T-cell function, and the local inflammatory environment. Experiments should combine Kyn/Trp ratio, T-cell proliferation, Treg proportion, and related cytokines.

8.3 Is elevated phenylalanine always caused by PAH deficiency?

Not necessarily. Elevated phenylalanine may be caused by PAH deficiency, but may also be associated with abnormalities in BH4 synthesis or regeneration, liver dysfunction, dietary intake, and sample status. If Phe is elevated, Tyr, Phe/Tyr ratio, pterin profile, and PAH-related tests should be combined for further evaluation.

8.4 Does increased TH mean dopamine must increase?

Not necessarily. TH is the rate-limiting enzyme in dopamine synthesis, but dopamine production is also affected by BH4, AADC/DDC activity, tyrosine availability, neuronal status, and dopamine degradation rate. L-DOPA, dopamine, DOPAC, HVA, and TH phosphorylation status should be measured together.

8.5 Why should cell viability be measured together with tyrosinase activity?

Many interventions can reduce melanin content through cytotoxicity or inhibition of proliferation, creating a false impression of tyrosinase inhibition. In melanin production experiments, TYR activity, melanin content, cell viability, and cell number-normalized results should be measured simultaneously.

Research on key enzymes in aromatic amino acid metabolism should establish a detection framework based on “substrate—enzyme—product—pathway branching.” The tryptophan pathway focuses on IDO1/TDO2 and kynurenine diversion; the phenylalanine pathway focuses on PAH and BH4-dependent reactions; the tyrosine pathway connects catecholamines, melanin, and organic acid degradation.